Search filters

FoRx Therapeutics AG raises EUR 10M Seed-Financing round

FoRx Therapeutics AG, a Basel-based biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress (DRS) pathways activated in cancer, completes a EUR 10M seed-financing round led by M...

MCAM Symalit acquires Recycling Activities from Minger Kunststofftechnik

MCAM Symalit AG, Lenzburg, a group company of the Mitsubishi Chemical Advanced Materials group, a leading global manufacturer of high-performance materials, takes over all Recycling related activities and assets, current...

Italian Wine Brands S.p.A. acquires Raphael Dal Bo AG

Raphael Dal Bo has sold his majority stake in Raphael Dal Bo AG, a leading producer of organic sparkling wine, to Provinco Italia S.p.A., a subsidiary of Italian Wine Brands S.p.A. (listed at AIM Italia).

VISCHER advised the...

Ricoh acquires Lake Solutions AG

The world-wide active Ricoh technology group acquires all shares in Lake Solutions AG, a leading Swiss ICT solutions Provider.

VISCHER advises the selling shareholders. The team is led by Felix W. Egli (Partner, Corporate/M&A)...

NUMAB concludes Licensing and Development Agreement in China

Suzhou, China and Pfäffikon SZ, Switzerland May 2, 2019 – CStone Pharmaceuticals ("CStone"; HKEX: 2616) and Numab Therapeutics AG ("Numab") have entered into an exclusive regional licensing agreement for the development and...

ALENTIS Therapeutics raises CHF 12.5m in Series A Financing

ALENTIS Therapeutics, a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer, announced today the completion of a Series A financing of CHF 12.5 million. ALENTIS’ lead program is a...

Polyneuron raises CHF 22.5 million in a major Series A financing

Polyneuron Pharmaceuticals AG, a developer of a new class of biodegradable glycopolymers for the treatment of autoimmune diseases, today announced the closing of an oversubscribed CHF22.5 million Series A financing. The round was...

USD 100 million debt financing by Hercules Capital to Urovant Sciences

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, has entered into a debt financing agreement with Hercules Capital,...

Arvelle Therapeutics raises USD 180 million in Series A financing

A global syndicate of investors led by LSP and including NovaQuest, BRV Capital Management, Andera Partners, and H.I.G. BioHealth Partners supported new company Arvelle Therapeutics with a USD 180 million financing to acquire the...

Anaveon closes CHF 35 m Series A financing

Anaveon, an immuno-oncology biotech, has successfully concluded a Series A financing round led by Syncona, a UK Life Sciences fund, and joined by the Novartis Venture Fund. The company was founded with financing from BaseLaunch,...

You are currently offline. Some pages or content may fail to load.